1,300 mg of aspirin daily does not cause positive fecal hemoccult tests.
ABSTRACT Americans 50 years of age and older are advised to test their stools for occult blood to detect colorectal neoplasms. Many will be taking 1,300 mg of aspirin daily because of cerebrovascular disease or smaller amounts for cardiovascular disease. To determine if 1,300 mg of aspirin causes positive hemoccult II tests, 27 healthy volunteers ate a red meat-free, high-fiber diet. Their stools were negative for occult blood during a 3-day control period and remained negative while they took 1,300 mg aspirin daily for an additional 7 days. This indicates that 1,300 mg aspirin daily for 1 week does not cause positive hemoccult II testing. Those taking this dose of aspirin probably need not interrupt therapy to perform hemoccult II testing.
- [Show abstract] [Hide abstract]
ABSTRACT: There are several approaches to the early detection of colorectal cancer that currently are in use in various segments of the health care system. Herein, the status of cancer control research regarding symptom and risk factor assessment, sigmoidoscopy and colonoscopy, double contrast barium enema, and fecal occult blood testing is reviewed. In addition to the different technologies of early cancer detection, there are different models of disease control intervention. These include the routine clinical activities of primary care providers as well as programmatic screening of mass populations. The currently available techniques for early colorectal cancer detection appear better suited for existing patient care settings than for programs outside the direct supervision and follow-up of the health professional.Seminars in Surgical Oncology 01/1986; 2(4):215-24. DOI:10.1002/ssu.2980020404
- [Show abstract] [Hide abstract]
ABSTRACT: Testing feces for occult blood is widely recommended as a means of detecting subclinical colorectal tumors. Guaiac tests such as Hemoccult are the most widely used, but chemical sensitivity is relatively low and the tests are affected by dietary peroxidases, the state of fecal hydration, and certain drugs. The newly devised HemoQuant and immunologic techniques appear more sensitive and specific, but they require further evaluation before widespread clinical usage can be recommended. Occult blood screening has both merits and weaknesses. Testing does uncover subclinical colorectal cancer, often at a relatively early stage, but whether this actually improves the prognosis remains to be proven. Benign neoplastic polyps are also detected, although it is debatable whether this is a valid rationale for screening. Test sensitivity for malignancy varies from good to moderate, but is poor for benign polyps. Specificity is usually around 97%-98%, yet the predictive value of a positive test for cancer is only about 10%; hence most test-positive individuals are needlessly subjected to invasive colonic investigations. Reported figures on public compliance with occult blood testing vary widely from excellent to poor. Published costs of screening are usually quite low, but these overlook important indirect and hidden expenses and are therefore misleading. On balance, the problems of occult blood testing currently appear to outweight the merits. This could change, however, with the newer testing techniques and with awaited mortality data from controlled clinical trials now underway.Cancer and metastasis reviews 02/1987; 6(3):397-411. DOI:10.1007/BF00144272 · 6.45 Impact Factor
- British medical journal (Clinical research ed.) 09/1987; 295(6595):446. DOI:10.1136/bmj.295.6595.446-a